GRT-R912 / Gritstone bio - LARVOL DELTA

Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV) (clinicaltrials.gov) - P1 | N=342 | Completed | Sponsor: Gritstone bio, Inc. | Active, not recruiting ➔ Completed

Trial completion • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV) (clinicaltrials.gov) - P1 | N=342 | Active, not recruiting | Sponsor: Gritstone bio, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2023 ➔ Mar 2024 | Trial primary completion date: Dec 2023 ➔ Mar 2024

Enrollment closed • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • IFNG

Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV) (clinicaltrials.gov) - P1 | N=340 | Recruiting | Sponsor: Gritstone bio, Inc.

New P1 trial • Human Immunodeficiency Virus • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • IFNG